Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

482 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A first nation-wide assessment of soil-transmitted helminthiasis in Fijian primary schools, and factors associated with the infection, using a lymphatic filariasis transmission assessment survey as surveillance platform.
Kim SH, Stothard JR, Rinamalo M, Rainima-Qaniuci M, Talemaitoga N, Kama M, Rafai E, Jang S, Kim JY, Oh YM, Kim EM, Hong ST, Lowry JH, Verweij JJ, Kelly-Hope LA, Choi MH. Kim SH, et al. Among authors: oh ym. PLoS Negl Trop Dis. 2020 Sep 25;14(9):e0008511. doi: 10.1371/journal.pntd.0008511. eCollection 2020 Sep. PLoS Negl Trop Dis. 2020. PMID: 32976499 Free PMC article.
Seasonal effect of PM2.5 exposure in patients with COPD: a multicentre panel study.
Huh JY, Kim H, Park S, Ra SW, Kang SY, Jung BH, Kim M, Lee SM, Lee SP, Lamichhane DK, Park YJ, Lee SJ, Lee JS, Oh YM, Kim HC, Lee SW. Huh JY, et al. Among authors: oh ym. Environ Sci Process Impacts. 2025 Jan 2. doi: 10.1039/d4em00376d. Online ahead of print. Environ Sci Process Impacts. 2025. PMID: 39744880
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial.
Singh D, Brightling CE, Rabe KF, Han MK, Christenson SA, Drummond MB, Papi A, Pavord ID, Molfino NA, Almqvist G, Kotalik A, Hellqvist Å, Gołąbek M, Sindhwani NS, Ponnarambil SS; COURSE study investigators. Singh D, et al. Lancet Respir Med. 2025 Jan;13(1):47-58. doi: 10.1016/S2213-2600(24)00324-2. Epub 2024 Dec 6. Lancet Respir Med. 2025. PMID: 39653044 Clinical Trial.
482 results